Alpha Cognition Inc. (ACOG)
NASDAQ: ACOG · Real-Time Price · USD
6.67
+0.17 (2.54%)
At close: Jun 26, 2026, 4:00 PM EDT
6.50
-0.17 (-2.48%)
After-hours: Jun 26, 2026, 4:10 PM EDT
Alpha Cognition Employees
Alpha Cognition had 71 employees as of December 31, 2025. The number of employees increased by 14 or 24.56% compared to the previous year.
Employees
71
Change (1Y)
14
Growth (1Y)
24.56%
Revenue / Employee
$152,471
Profits / Employee
-$358,068
Market Cap
141.53M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 71 | 14 | 24.56% |
| Dec 31, 2024 | 57 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| ADC Therapeutics | 193 |
| Humacyte | 184 |
| Molecular Partners AG | 134 |
| Tenaya Therapeutics | 70 |
| Connect Biopharma Holdings | 64 |
| Pyxis Oncology | 56 |
| Corbus Pharmaceuticals Holdings | 36 |
| Enlivex | 34 |
ACOG News
- 4 days ago - Alpha Cognition appoints Robert Wills as chairman of the board - TheFly
- 4 days ago - Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board - Business Wire
- 11 days ago - Alpha Cognition announces enrollment of first patient in Resolve - TheFly
- 11 days ago - Alpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL® in Patients with Mild to Moderate Alzheimer's Disease - Business Wire
- 18 days ago - Alpha Cognition reports results from Beacon real-world study of Zunevyl - TheFly
- 18 days ago - Alpha Cognition Reports Positive Top-Line Results from BEACON Real-World Study of ZUNVEYL® in Alzheimer's Disease - Business Wire
- 4 weeks ago - Maxim starts Alpha Cognition at Buy, sees ‘significant’ market opportunity - TheFly
- 4 weeks ago - Alpha Cognition initiated with a Buy at Maxim - TheFly